General surgery: 2 trials - Bergqvist [42] - Leizorovicz
| tinzaparin vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Symptomatic pulmonary embolism | 0.35 [0.01 8.87] | p=1.00 | 0 | 80 | 1 | Bergqvist [42], | | asymptomatic DVT | 0.35 [0.09 1.41] | p=1.00 | 0 | 80 | 1 | Bergqvist [42], | | Symptomatic venous thromboembolism (DVT, PE) | no data | | wound haematoma / infection | 1.05 [0.02 54.31] | p=1.00 | 0 | 80 | 1 | Bergqvist [42], | | transfusion | no data | | Bleeding | 5.26 [0.24 113.14] | p=1.00 | 0 | 80 | 1 | Bergqvist [42], | | Major bleeding | 3.15 [0.12 79.84] | p=1.00 | 0 | 80 | 1 | Bergqvist [42], | | All cause death | 0.21 [0.01 4.53] | p=1.00 | 0 | 80 | 1 | Bergqvist [42], |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| tinzaparin vs unfractionated heparin | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Symptomatic pulmonary embolism | 1.25 [0.24 6.45] | p=1.00 | 0 | 1290 | 1 | Leizorovicz, | | asymptomatic DVT | 1.64 [0.70 3.85] | p=1.00 | 0 | 1290 | 1 | Leizorovicz, | | Symptomatic venous thromboembolism (DVT, PE) | no data | | wound haematoma / infection | no data | | transfusion | no data | | All cause death | 1.11 [0.50 2.45] | p=1.00 | 0 | 1290 | 1 | Leizorovicz, | | Bleeding | no data | | Major bleeding | 0.78 [0.40 1.55] | p=1.00 | 0 | 1290 | 1 | Leizorovicz, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Orthopedic surgery: 1 trials - Lassen
| tinzaparin vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| total VTE and all-cause mortality | no data | | major or clinically relevant non-major bleeding | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Patients with immobilization of the lower extremities: 1 trials - Jorgensen
| tinzaparin vs control | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Venous thromboembolism | 0.59 [0.26 1.36] | p=1.00 | 0 | 205 | 1 | Jorgensen, | | Symptomatic venous thromboembolism (DVT, PE) | 1.07 [0.02 54.49] | p=1.00 | 0 | 205 | 1 | Jorgensen, | | total VTE and all-cause mortality | no data | | major or clinically relevant non-major bleeding | no data | | Minor bleeding | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| Tinzaparin vs acenocoumarol | No demonstrated result suggested recurrent DVT by 79% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Recurrent thromboembolic event | 0.47 [0.17 1.29] | p=1.00 | 0 | 241 | 1 | Romera, | | puylmonary embolism | 1.37 [0.30 6.24] | p=1.00 | 0 | 241 | 1 | Romera, | | recurrent DVT | 0.21 [0.04 0.96] | p=0.04 | 0 | 241 | 1 | Romera, | | VTE during active anticoagulant treatment | 0.73 [0.23 2.37] | p=1.00 | 0 | 241 | 1 | Romera, | | VTE during follow-up after active anticoagulant treatment | 0.17 [0.02 1.44] | p=1.00 | 0 | 241 | 1 | Romera, | | Bleeding | 0.34 [0.04 3.33] | p=1.00 | 0 | 241 | 1 | Romera, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| Tinzaparin vs unfractionated heparin | No demonstrated result suggested Short term haemorrhage by 91% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Recurrent thromboembolic event | 0.41 [0.16 1.08] | p=1.00 | 0 | 432 | 1 | Hull et al , | | Thrombus extension | no data | | All cause death | 0.49 [0.22 1.07] | p=1.00 | 0 | 432 | 1 | Hull et al , | | Short term haemorrhage | 0.09 [0.01 0.73] | p=0.04 | 0 | 432 | 1 | Hull et al , |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| Tinzaparin vs warfarin | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Recurrent thromboembolic event | no data | | puylmonary embolism | no data | | recurrent DVT | no data | | VTE during active anticoagulant treatment | 0.76 [0.39 1.48] | p=1.00 | 0 | 737 | 1 | Hull, | | VTE during follow-up after active anticoagulant treatment | 1.00 [0.48 2.08] | p=1.00 | 0 | 688 | 1 | Hull, | | Bleeding | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
